A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned
Fig 6
Levels of binding antibodies prior to infection correlate with reduced viral burden in BAL post-infection.
Correlations between BAL viral load (VL) burden measured as area under the curve (AUC) and peak, pre-challenge and/or post-challenge (7 DPI) of Serum anti-S IgG ELISA (top panels 1–3), PRNT80 antibody titers against the SARS-CoV2/WA/2020 isolate (middle panels 4–6), and/or Magnitude of IFN-γ T-cell analysis responses measured in PBMCs following stimulation with SARS-CoV-2 spike peptides evaluated by IFN-γ ELISpot assay (bottom panels 7–9). Dots represent individual animals in the groups receiving 5 μg (pink), 25 μg (teal), or 50 μg (purple) repRNA-COV2 vaccines. Spearman’s rank correlation is shown, with p-values ≤ 0.05 considered significant.